Participated · Series A · May 2025

Rhino Federated Computing provides a platform for federated AI collaboration that enables enterprises to run AI and data science initiatives without centralizing data. The platform emphasizes protecting data ownership, complying with regulation, and accelerating multi‑party innovation. Founded in 2020 by Dr. Ittai Dayan and Yuval Baror, the company is based in Boston and maintains an R&D center in Tel Aviv. Rhino is already powering use cases including federated GenAI for biopharmaceutical R&D, healthcare data harmonization and federated collaboration, and financial‑crime and fraud detection for financial institutions. The company raised $15M in a Series A and has now raised over $30M to date. Rhino plans to use the new capital to scale capabilities across more customers and regulated sectors and to bring an enterprise‑grade federated AI solution to market. Rhino Health builds healthcare AI infrastructure that connects medical data sources with researchers while preserving patient privacy and IP confidentiality. The company develops solutions using federated learning and edge computing to enable secure, decentralized data processing and AI model training. Rhino Health has enabled partners to create networks of health systems, life sciences companies, and public sector organizations for cross-continent data collaborations. Led by CEO Dr. Ittai Dayan, the company emphasizes privacy-preserving approaches to accelerate healthcare research. The company received an investment intended to fund continued design of its federated and edge computing solutions; the amount was not disclosed. Rhino Health operates a platform that connects hospitals and AI developers, providing access to a large, continually updated, distributed dataset from a diverse group of patients. The core product enables clinical AI model development across different institutions and patient demographics. Rhino is collaborating with NVIDIA to bring federated learning into clinical settings and is using NVIDIA Clara to support cross-geography and cross-device model training. The company is a member of the NVIDIA Inception program and maintains an R&D center in Tel Aviv, Israel. Rhino closed a $5M seed financing round led by LionBird Ventures, with participation from Arkin Holdings and several angel investors. The company is led by CEO Ittai Dayan, MD, and CTO Yuval Baror.

Participated · Seed · Nov 2024

Revisto is an AI-powered platform that automates and streamlines the medical, legal, and regulatory (MLR) review workflow for pharmaceutical marketing materials. Its engine was developed using terabytes of proprietary pharmaceutical data and leverages customers’ brand-specific data plus real-time FDA 21 CFR regulations and guidelines to detect and recommend changes. The solution integrates with existing review workflows and CMS software such as Veeva Vault PromoMats to shorten review cycles and reduce compliance risk. Revisto projects it can save life-sciences clients an estimated $15 million or more per brand annually by cutting time and cost associated with MLR reviews. The company plans to expand its team and accelerate product development to increase the depth and breadth of what its engine can detect and recommend and to broaden its services. Financially, Revisto announced a $4M seed round that brings total funding to $6M; the company currently has more than ten team members and is based in Austin, Texas.

Participated · Seed · Feb 2024

Siftwell Analytics builds AI-driven analytics to empower community-oriented organizations and community-based health plans with actionable insights for improved member outcomes. The company emphasizes tailored, operationally contextualized data products designed for underserved and vulnerable populations. Leadership says the product enables data-driven decisions that align with the needs of community plans. Siftwell aims to partner with community-based health plans to advance equitable care. The company announced it secured $5.8 million in seed funding to support that mission. The funding is intended to propel growth and further development of its AI analytics offerings.

Participated · Series B · Nov 2023

Eleos builds AI agents and multimodal LLM-powered tools that streamline clinical documentation, surface care insights, and improve patient engagement for behavioral health providers. The company recently launched Eleos Compliance, a clinical documentation improvement (CDI) product that uses agentic AI to flag documentation errors and simplify appeals and accreditation work. Eleos uses the industry’s largest dataset of real-world treatment sessions and claims randomized controlled trial results showing >80% faster progress note submission, doubled client engagement, and 3–4x improved care outcomes versus treatment as usual. The company has more than 120 customer organizations across 30+ U.S. states and reports rapid revenue growth, tripling annual revenue over its first three years and doubling revenue in 2024. Eleos plans to use new funding to expand product offerings, grow its commercial team, hire senior leaders and engineering/data talent, and push into underserved segments—particularly substance use disorder and post-acute behavioral healthcare. Eleos Health develops AI that interprets, analyzes and documents behavioral health conversations using proprietary, behavioral health–specific large language models trained on treatment data and clinical expertise. The system reduces operational burden on providers by automating documentation and surfacing objective insights into evidence-based care and the therapeutic alliance. Leadership teams can scale supervision and training and gain visibility into staff activity, caseloads, performance and population health. The company plans new and enhanced AI solutions for group therapy, compliance automation, case management, concurrent documentation and value‑based care support. Eleos intends to expand its reach to more behavioral health providers and segments, deepen strategic partnerships with EHRs and industry associations, and hire more than 50 people by the end of 2024. It is led by CEO Alon Joffe and is based in Boston and Tel Aviv. Eleos Health provides CareOps Automation solutions that consolidate the behavioral care workflow by automating operational necessities, including documentation and compliance administration, and by delivering session intelligence. Its session intelligence tools generate clinical insights that enable clinicians, providers, and networks to track treatment and progress in a measurable way. The company is led by CEO Alon Joffe and is used by thousands of clinicians across more than 20 national care providers and health plans, including Gaudenzia Home, The Brookline Center for Mental Health, and Coleman Health Services. Eleos has captured more than 6.5 million minutes of treatment to date and is projecting 30 million minutes captured by the end of 2022. The company intends to use the funding to accelerate growth and expand its operations, team, and product. Eleos is based in Boston, MA. Eleos Health develops an AI-powered Speech-to-Insights system that analyzes behavioral health sessions to surface actionable insights for clinicians. Its VoiceAI technology runs securely in the background of sessions and analyzes hundreds of data parameters to accelerate clinical decision-making and personalize care. The company has deployed its solution with over a dozen provider organizations, including Solvista Health, Achieve, Yeshiva University and ReachLink. Eleos plans to use the recent funding to expand sales, marketing, and solution delivery teams needed to meet demand for enterprise software deployments across providers and payors. Founded in 2020 and based in Boston and Tel Aviv, the company has added Dr. David Shulkin to its board. Eleos closed a $6M seed round in 2021.

Participated · Seed · Jan 2023

Nest Genomics offers an end-to-end, EMR-integrated platform that incorporates genomics into clinical workflows, including clinical decision support and patient engagement tools. The lab-agnostic, turnkey solution supports hereditary cancers, cardiovascular genetics, and conditions on the ACMG secondary findings list. Nest has launched in several large health systems and enables providers to create care plans based on clinical guidelines and patient data. The founders, Moran Snir and Guy Snir, previously built Clear Genetics (acquired by Invitae in 2019) and aim to increase access to genetic services. Nest plans to expand integrations with more EMRs, broaden clinical specialty coverage (including Pediatrics, polygenic risk scores, and pharmacogenetics), and automate additional parts of the genetic testing process. The company recently closed a Seed financing to fund customer launches, EMR integrations, and product expansion.